Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic ...

By sharing her own experiences and helping athletes see their value, Anne has truly become the ultimate “coach.” When she ...

Colorectal cancer (CRC) is the second most common cause of death from cancer in the US and the most prevalent malignant tumor ...

Colorectal cancer (CRC) is the second most common cause of death from cancer in the United States (US) and the most prevalent ...

In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug ...

New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, ...

Top-line results from a Phase III trial showed an overall survival benefit for zanzalintinib combo therapy in microsatellite-stable colorectal cancer.

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety ...

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations.

Colorectal cancer happens when cells in the colon or rectum (parts of the large intestine) begin to grow out of control. This happens because of changes, or mutations, in the DNA inside the cells. But ...